Evaluation of the Effect of Periimplant Soft Tissue Phenotype on Marginal Bone Loss
NCT ID: NCT05640284
Last Updated: 2023-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
87 participants
OBSERVATIONAL
2022-12-02
2023-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Is keratinized mucosal thickness (KMT) important in early marginal bone loss and peri implant health?
2. Is keratinized gingival width (KGW) important in early marginal bone loss and and peri implant health? The researchers plan to include 80 implants in the study. These 80 implants will be divided into 2 groups in 2 different ways according to their KMT and KGW on their buccal surfaces: KMT ≥2 mm are included in the adequate KMT, and those with KMT\<2 mm are in the insufficient KMT group. Those with KGW≥2 mm are adequate KGW, those with KGW\<2 mm are adequate KGW. The researchers will assess marginal bone loss around the implant using radiographs and collect peri-implant crevicular fluid (PICF) using paper strips. Another researchers will measure the Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL), Osteoprotegerin (OPG), Tumor Necrosis Factor Alpha (TNF-α), MicroRNA-223 (MiRNA-223), MicroRNA-27a (MiRNA-27a) levels in the collected PICF. They will compare radiographic bone loss and biomarker levels in groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nonsurgical Periodontal Treatment Combined With Anti-TNF-α in Patients With Rheumatoid Arthritis and Periodontitis
NCT06818045
Evaluation of Bone Metabolism Biomarkers in Periodontal Diseases
NCT05702892
Comparison of Saliva Biomarkers in Two Different Geographical Regions of Turkey
NCT06809439
Tissue Alterations in Aggressive and Chronic Periodontitis
NCT03625414
Comparison of Current Subgingival Debridement Methods
NCT06835452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The hypothesis of this study: Periimplant soft tissue phenotype is associated with marginal bone loss and peri implant health through Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL), Osteoprotegerin (OPG), Tumor Necrosis Factor Alpha (TNF-α), MicroRNA-223 (MiRNA-223) and Microrna-27a 80 implants, at least 1 year after their loading, in patients who continued their routine controls will be included in the study. The participants in this study were selected from patients who underwent implant placement by the same periodontologist (E.Ö.) in the Department of Periodontology of Necmettin Erbakan University in 2020 and still have 6-month radiographic and clinical follow-up. Selected patients, those who signed the written informed consent form were included in the study. In the study, the first radiographs of all patients, the clinical and radiographic conditions obtained at the 6-month routine control examination will be evaluated. During the same routine controls, a sample of peri-implant groove fluid was taken with paper strips.
Diagnoses of the implants included in the study will be made using the criteria of the 2017 World Workshop on Periodontal and Peri-implant Diseases and Conditions. 2 mm marginal bone loss (MBL) which may occur during the bone remodeling process after implant placement and loading, is accepted as the threshold. The absence of signs of inflammation (redness, swelling, bleeding on probing) in the peri-implant soft tissue, probing depth (PD) ≤5 mm with mild force (approximately 0.25 N), and no further bone loss following initial healing are defined as "periimplant health". "Peri-implant mucositis" is defined as clinically observable signs of inflammation (swelling, redness and soft consistency of tissue), bleeding on probing (BOP) (lines or drops) and/or signs of suppuration in the absence of bone loss greater than 2 mm, the threshold for initial bone remodulation defined. The definition of "peri-implantitis" is clinically observable signs of inflammation, probing bleeding and/or suppuration, increased probing depth, progressive bone loss after implant restoration, or MBL ≥3 mm with profuse bleeding in the absence of initial radiographs and PD was ≥6 mm. Implants with periimplantitis will be excluded. Implants will be divided into 2 groups according to their peri-implant health: Peri-implant health and peri-implant mucositis.
In addition to routine clinical and radiographic examination of the implants, KMT and KGW measurements will be made. they will be divided into 2 groups in 2 ways. According to KMT on their buccal surfaces: KMT ≥2 mm are included in the adequate KMT, and those with KMT \<2 mm are in the inadequate KMT group (60). According to KGW on their buccal surfaces: KGW≥2 mm are adequate KGW, those with KGW\<2 mm are inadequate KGW.
Radiographic evaluation will be made using intraoral periapical radiographs obtained using the parallel technique with the plastic film holder. Calibration of digital images will be performed using the length of the implant as a well-defined fixed reference point. The bone level measurement will be made by measuring between the bone-implant first contact point and the reference point in the coronal part of the implant body selected for different implant systems in both the mesial and distal directions of the implants. In order to evaluate the marginal bone loss (MBL), the measurements obtained will be compared with the measurements on the radiographs taken after the delivery of the prosthesis.
Peri-implant crevicular fluid (PIGF) will be collected from the participants for the biochemical evaluation to be made. PIGF specimens will be collected from the mesiobuccal of each implant, prior to any periodontal probing, and after removal of the supra mucosal plate. The area to be sampled will be insulated with cotton rolls and air-dried. The paper will be advanced with the strip until it shows slight resistance and held in the sample area for 30 seconds. Samples will be stored at -70˚C.
TNF-α, RANKL, OPG and MiRNA 223 and MiRNA 27a evaluations of the peri-implant crevicular fluid (PIGF) collected from the patients will be performed. TNF-α, RANKL and OPG will be evaluated by the Enzyme-Linked ImmunoSorbent Assay (ELISA) method. MiRNA 223 and MiRNA 27a evaluations will be performed using Real-Time Polymerase Chain Reaction (RT-PCR).
Marginal bone loss and biomarker levels will be compared between the groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adequate KMT
Keratinized mucosal thicknesses (KMT) on their buccal surfaces are 2 mm and above.
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
inadequate KMT
Keratinized mucosal thicknesses (KMT) on their buccal surfaces are less than 2 mm.
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
adequate KGW
keratinized gingival width (KGW) on their buccal surfaces are 2 mm and above.
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
inadequate KGW
keratinized gingival width (KGW) on their buccal surfaces are less than 2 mm.
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
Peri-implant health
The absence of signs of inflammation (redness, swelling, bleeding on probing) in the peri-implant soft tissue, probing depth (PD) ≤5 mm with mild force (approximately 0.25 N), and no further bone loss following initial healing are defined as "peri-implant health".
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
peri-implant mucositis
"Peri-implant mucositis" is defined as clinically observable signs of inflammation (swelling, redness and soft consistency of tissue), bleeding on probing (lines or drops) and/or signs of suppuration in the absence of bone loss greater than 2 mm, the threshold for initial bone remodulation.
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nuclear Factor-Kappa B Ligand (RANKL) analysis
samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Osteoprotegerin (OPG) analysis
samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Tumor Necrosis Factor Alpha (TNF-α) analysis
samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
MicroRNA-223 analysis
samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Microrna-27a analysis
samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over-implant restoration, functioning for at least 12 months
* Attending our preventive care regularly (≥1/year)
* Non-smokers
Exclusion Criteria
* Bisphosphonate users
* Those who have received antibiotic treatment in the last 3 months
* Patients with diabetes mellitus (hemoglobin A1c ≥7.0) that may affect the outcome of implant therapy
* implants with peri-implantitis
* Pregnant or breastfeeding mothers
* Those with metabolic bone disorders
* Those who have a history of periodontitis and have undergone any periodontal treatment in the last year
* Those whose implant positions are not suitable
* Implants using soft or hard tissue grafts before, during, or after implant placement
* Those with a restoration that did not allow accurate probing depth recording were excluded from the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Necmettin Erbakan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeynep Tastan Eroglu
assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
zeynep taştan eroğlu
Role: STUDY_DIRECTOR
Necmettin Erbakan University
dilek özkan şen
Role: PRINCIPAL_INVESTIGATOR
Necmettin Erbakan University
elif öncü
Role: PRINCIPAL_INVESTIGATOR
Lokman Hekim University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Necmettin Erbakan University, dentistry Faculty
Konya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
periimplantmicrorna
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.